General Patterns of Candida susceptibility to antifungal agents: fluconazole, itraconazole, voriconazole, posaconazole, amphotericin B, flucytosine, candins
C. albicans: S to all C. tropicalis: S to all C. parapsilosis: S to all except S-R for candins C. lusitaniae: S to all except S-R for amphotericin B C. glabrata: S to flucytosine/candins; S-I to ampho B; S-DD to R for all others
C. krusei: S to voriconazole/posaconazole/candins; S-I to ampho B; S-DD to R for itraconazole; I-R for flucytosine; R for fluconazole S = sensitivity, I = intermediate, R = resistance, S-DD = susceptible dose dependent
Strength of Recommendation and Evidence Quality Strength A B C
Definition
Quality I
II III
Good evidence for or against a recommendation Moderate evidence for or against a recommendation Poor evidence to support a recommendation Definition
Evidence from ≥ 1 randomized, controlled trial
Evidence from ≥ 1 clinical trial, without randomization; from cohort or case-controlled analytic studies (preferably from > 1 center); from multiple time-series; or dramatic results from uncontrolled experiments
Opinions of respected authorities, based on experience, descriptive studies, or reports of expert committees
Disclaimer
This Guideline attempts to define principles of practice that should produce high-quality patient care. It focuses on the needs of primary care practice, but also is applicable to providers at all levels. This Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. The ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aſter consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool.
5740 Executive Drive Suite 220 Baltimore, MD 21228 TEL: 410-869-3332 • FAX: 410-744-2150 For additional copies: orders@GuidelineCentral.com Copyright © 2010 All rights reserved
